Gallagher Susan, Johnstone Alice, De Livera Alysha, Marsh Deborah J, Walsh Sean
School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, Sydney, New South Wales, 2007, Australia.
School of Science, RMIT University, Melbourne, VIC, Australia.
J Cancer Surviv. 2024 Jul 31. doi: 10.1007/s11764-024-01647-7.
More women diagnosed with breast cancer (BC) are living with oncology treatment-induced hot flushes (HFs). This Australian-based survey explores why some women experience more severe or ongoing HF and whether specific population characteristics are predictive of HF occurrence, frequency, and/or severity.
A non-probabilistic anonymous survey distributed online (Register4) and two Australian hospitals collected demographic and clinical information. Eligibility was consenting Australian-based women, 18 years and over, with a primary BC diagnosis. Analysis included linear and logistic regression models.
A total of 324 survey responses were analyzed. Chemotherapy and hormone therapy were each associated with HF occurrence (aOR = 2.92, 95% CI [1.27, 6.70], p = 0.01; and aOR = 7.50, 95% CI [3.02, 18.62], p < 0.001) and in combination (aOR = 5.98, 95% CI [2.61, 13.69], p < 0.001). Increased self-reported anxiety at BC diagnosis was significantly associated with HF frequency and severity scores (aCO = 0.71, 95% CI [0.31, 1.12], p = 0.001; and aCO = 0.44, 95% CI [0.33, 0.55], p < 0.001). Postmenopausal women had significantly lower HF severity and frequency scores than premenopausal women (aCO = -0.93, 95% CI [-1.62, -0.25], p = 0.008; and aCO = -2.62, 95% CI [-5.14, -0.11], p = 0.041).
Women with BC receiving chemotherapy and/or hormone therapy and premenopausal or experiencing elevated anxiety and/or stress will likely experience more severe oncology treatment-related HFs.
HFs continue across the BC treatment trajectory with women >5-year survivorship still reporting life impacts, with premenopausal women at the time of BC diagnosis at higher risk of experiencing severe and more frequent oncology treatment-induced HFs than postmenopausal women. Women at high risk require information on methods to moderate HF potential life impacts and maintain treatment compliance.
越来越多被诊断出患有乳腺癌（BC）的女性正在经历肿瘤治疗引起的潮热（HFs）。这项基于澳大利亚的调查探讨了为什么有些女性会经历更严重或持续的潮热，以及特定的人口统计学特征是否能预测潮热的发生、频率和/或严重程度。
通过在线（Register4）分发的非概率匿名调查以及澳大利亚的两家医院收集了人口统计学和临床信息。符合条件的是同意参与调查的18岁及以上的澳大利亚女性，她们被诊断为原发性乳腺癌。分析包括线性和逻辑回归模型。
共分析了324份调查回复。化疗和激素治疗均与潮热的发生相关（调整后比值比[aOR]=2.92，95%置信区间[CI][1.27, 6.70]，p = 0.01；aOR = 7.50，95% CI[3.02, 18.62]，p < 0.001），两者联合使用时相关性更强（aOR = 5.98，95% CI[2.61, 13.69]，p < 0.001）。自我报告的乳腺癌诊断时焦虑增加与潮热频率和严重程度评分显著相关（调整后协变量系数[aCO]=0.71，95% CI[0.31, 1.12]，p = 0.001；aCO = 0.44，95% CI[0.33, 0.55]，p < 0.001）。绝经后女性的潮热严重程度和频率评分显著低于绝经前女性（aCO = -0.93，95% CI[-1.62, -0.25]，p = 0.008；aCO = -2.62，95% CI[-5.14, -0.11]，p = 0.041）。
接受化疗和/或激素治疗的乳腺癌女性以及绝经前女性或焦虑和/或压力升高的女性可能会经历更严重的与肿瘤治疗相关的潮热。
在乳腺癌治疗过程中潮热持续存在，超过五年生存期的女性仍报告有生活影响，乳腺癌诊断时的绝经前女性比绝经后女性更有可能经历严重且更频繁的肿瘤治疗引起的潮热。高危女性需要了解减轻潮热对生活潜在影响并维持治疗依从性的方法。
